LaNua Medical develops the ECORE™ device, a targeted embolization technology that blocks blood flow to specific tissues, enabling precise therapeutic delivery for conditions such as vascular diseases and tumors. This approach addresses the challenges of internal bleeding and unwanted embolization reflux, enhancing the safety and effectiveness of minimally invasive procedures.
Funding
$6.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current embolization techniques for treating vascular diseases and tumors face challenges related to internal bleeding and the risk of unwanted embolization reflux, potentially limiting the safety and effectiveness of minimally invasive procedures. Existing solutions may not offer sufficient precision in blocking blood flow to targeted tissues.
Solution
LaNua Medical is developing the ECORE™ device, an image-guided technology designed to provide targeted embolization for treating vascular diseases and tumors. The ECORE™ device aims to block blood flow to select tissue while enabling targeted therapeutic delivery, reducing the risk of side effects. This emerging technology offers an innovative solution for unwanted embolization reflux. The device is designed to be adaptable for use in many areas of the human body to treat multiple disease states.
Target Audience
The primary target audience includes interventional radiologists and other medical professionals who perform embolization procedures for treating vascular diseases and tumors.
Features
- Targeted embolization to block blood flow to specific tissues.
- Minimally invasive procedure for treating internal bleeding, benign tumors, and malignant tumors.
- Designed to reduce the risk of unwanted embolization reflux.
- Adaptable for use in multiple areas of the human body.
- Image-guided technology for precise therapeutic delivery.